Insider Selling: NPS Pharmaceuticals CFO Sells 50,000 Shares of Stock (NPSP)
NPS Pharmaceuticals (NASDAQ:NPSP) CFO Luke Beshar unloaded 50,000 shares of NPS Pharmaceuticals stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $30.26, for a total value of $1,513,000.00. Following the transaction, the chief financial officer now directly owns 59,180 shares of the company’s stock, valued at approximately $1,790,787. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of NPS Pharmaceuticals (NASDAQ:NPSP) in a research note to investors on Friday. They set an “overweight” rating and a $40.00 price target on the stock. Separately, analysts at Leerink Swann set a $35.00 price target on shares of NPS Pharmaceuticals (NASDAQ:NPSP) in a research note to investors on Thursday, September 5th. They now have an “outperform” rating on the stock. Finally, analysts at Oppenheimer raised their price target on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $19.00 to $28.00 in a research note to investors on Wednesday, August 21st. They now have an “outperform” rating on the stock.
Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $26.03.
NPS Pharmaceuticals (NASDAQ:NPSP) traded up 0.64% during mid-day trading on Tuesday, hitting $31.24. The stock had a trading volume of 1,260,202 shares. NPS Pharmaceuticals has a 52-week low of $7.35 and a 52-week high of $31.72. The stock’s 50-day moving average is $25.29 and its 200-day moving average is $16.90. The company’s market cap is $3.169 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last announced its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.06. The company had revenue of $36.50 million for the quarter, compared to the consensus estimate of $31.62 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The company’s revenue for the quarter was down 31.8% on a year-over-year basis. On average, analysts predict that NPS Pharmaceuticals will post $-0.20 earnings per share for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.